The Priority Review

Tag

Eli Lilly and Company

7 stories

Stories

  1. Policy

    Eli Lilly launches Life Doesn't Slow Down campaign for Foundayo

    The company announced a new campaign encouraging patients to discuss weight-loss options with doctors. The campaign highlights Foundayo, a GLP-1 pill approved by the FDA in April 2026, and features comedian Leanne Morgan as a spokesperson.

  2. Clinical trials

    Eli Lilly registers Phase 3 study of EloraTZP in obesity

    The study, NCT07881432 (AMPLIFY-1), was first posted on ClinicalTrials.gov on October 19, 2026. It plans to enroll 2115 participants, start in December 2026, and reach primary completion in October 2029.

  3. Clinical trials

    Eli Lilly registers Phase 3 study of EloraTZP in obesity and type 2 diabetes

    The study plans to enroll 1000 participants, start in November 2026, and reach primary completion in October 2029. It aims to investigate the efficacy and safety of the eloralintide and tirzepatide coformulation (EloraTZP) compared to tirzepatide in adults with obesity or overweight and type 2 diabetes.

  4. Clinical trials

    Eli Lilly posts results of Phase 3 lebrikizumab trial in atopic dermatitis

    Results for the Phase 3 trial of lebrikizumab with or without topical corticosteroid treatment in participants with moderate-to-severe atopic dermatitis were first posted on ClinicalTrials.gov on October 16, 2026. The completed study enrolled 301 participants and began on April 24, 2024.

  5. Clinical trials

    Eli Lilly posts results of Phase 3 orforglipron vs dapagliflozin study

    The company posted results for the ACHIEVE-2 study, a Phase 3, randomized, open-label trial that enrolled 962 participants with type 2 diabetes. The study compared once-daily oral orforglipron (LY3502970) with dapagliflozin and completed primary data collection on September 26, 2025.

  6. Approvals

    FDA approves pirtobrutinib for previously untreated CLL or SLL

    The FDA approved pirtobrutinib (Jaypirca, Eli Lilly and Company) on October 2, 2026 for adult patients with previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma with no known 17p deletion. The approval follows the BRUIN CLL-313 trial, which enrolled 282 patients and showed a median progression-free survival that was not estimable versus 33.5 months for bendamustine plus rituximab.

  7. Clinical trials

    Results posted for phase 3 orforglipron study in type 2 diabetes

    Results for this study were first posted on ClinicalTrials.gov on October 1, 2026. The study enrolled 546 participants and completed primary data collection on September 15, 2025.